Management of severe bleeding in patients taking oral anticoagulants is complicated. Acute care physicians must be knowledgeable about the individual oral anticoagulant agents, the general management of anticoagulant-associated bleeding, and the strategies for effective use of factor repletion and specific reversal agents. With any oral anticoagulant, minor or “nuisance” bleeding is most common and can be managed without repletion or reversal. For major oral anticoagulant-associated bleeding, class-specific approaches should be used and the necessary treatment agents made readily available in the Emergency Department (ED), the Intensive Care Unit (ICU), and the surgical suite. Because the reversal agents for warfarin, the thrombin inhibitor dabigatran and the Factor Xa inhibitors apixaban and rivaroxaban are expensive and, like all therapies, have the potential for causing their own adverse events, acute care physicians must be sufficiently informed as to the risks and benefits before using these important new therapies.
These expert specialists will describe the implications of managing hyperkalemia in their field with patients in the Emergency Department, Critical Care Units, and the Cardiology Clinic. Finally, an EMCREG-International Hyperkalemia Consensus Panel algorithm for the approach to management of patients with life-threatening hyperkalemia.
is provided for the clinician and can be expanded in size for use in a treatment area such as the Emergency Department or Critical
For emergency physicians, critical care physicians, hospitalists, cardiologists, internists, surgeons, and family physicians, the current approach and disease indications for treatment with anticoagulants such as coumadin, Factor IIa, and Factor Xa inhibitors are particularly relevant. When a patient treated with anticoagulants presents to the Emergency Department, Intensive Care Unit, or Operating Room with severe, uncontrollable bleeding, achieving rapid, controlled hemostasis is critically important to saving the patient’s life.
In this EMCREG-International Monograph you will find a detailed discussion regarding the treatment of patients requiring anticoagulation and the reversal of anticoagulation for patients with severe bleeding.
In this EMCREG-International Monograph you will find a detailed discussion regarding the treatment of this important disease entity, acute coronary syndrome (ACS), which impacts millions of patients across the United States each year. This is a “state of the art” Monograph for emergency physicians, cardiologists, and hospitalists which provides the evidence basis for the optimal approach to treating ACS.
In this EMCREG-International Monograph, Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease, you will find a detailed discussion regarding the treatment of these two critically important disease entities. For cardiologists, internists, family physicians, hospitalists and emergency physicians, the current approach and evolution of treatment for stable coronary artery disease (CAD) and peripheral artery disease (PAD) are particularly relevant and represent a fertile area for improving care for these patients.
In this EMCREG-International Monograph you will find a detailed discussion regarding the use of high sensitivity troponin assays in patients presenting to the hospital with ACS from multiple perspectives including Emergency Medicine, Cardiology, Hospital Medicine, Laboratory Medicine, and Emergency Nursing.
In this EMCREG-International Monograph, you will find a variety of cardiovascular articles which will hopefully be helpful to you in your practice of Emergency Medicine and Acute Care Medicine. These topics which are extremely important to emergency physicians, hospitalists, and other acute care providers such as physician assistants and nurse practitioners as they care for these often critically-ill patients.
Join faculty experts as they review Emergency Physicians and Hospitalists care daily for patients who are critically ill and injured. The management of these patients is often complex and requires detailed diagnostic and therapeutic information, as well as a thorough understanding of disease pathophysiology.
This monograph covers advances in cardiac biomarker diagnostics including high-sensitivity troponin assays and CT coronary angiography, novel anticoagulant therapy, advances in antiplatelet therapy which have been incorporated into the latest ACCF/AHA guidelines, the interventional cardiologists perspective, and novel diagnostics for determining a patient’s clotting status by thromboelastography.